Free Shipping On Orders Over $1,000!

Cytokeratin 8 + 18 (8C12) Monoclonal Antibody

Applications

  • WB
  • FCM
  • IHC-P
  • IF(ICC)
  • IHC

Reactivity

  • Human
  • Mouse
Overview
Catalog # bsm-52419R
Product Name Cytokeratin 8 + 18 (8C12) Monoclonal Antibody
Applications WB, FCM, IHC-P, IF(ICC), IHC
Reactivity Human, Mouse
Specifications
Conjugation Unconjugated
Host Rabbit
Source Full length protein
Clonality Monoclonal
Clone # 8C12
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition Store at -20°C for 12 months.
Target
Swiss Prot P05783, P05787
Synonyms KeRatin, type II cytoskeletal 8, CytokeRatin-8, KeRatin-8, Type-II keRatin Kb8, KeRatin, type I cytoskeletal 18, Cell prolifeRation-inducing gene 46 protein, CytokeRatin-18, KeRatin-18, CK-8, K8, KRT8, CYK8, CK-18, K18, KRT18, CYK18
Background Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. They have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 8 expression is seen in epithelium and epithelium-derived tumors. The Cytokeratin 8 and 18 pair are normally expressed in simple epithelia, but not in stratified epithelial cells. Research indicates that squamous cell carcinomas derived from stratified epithelia show abnormal expression of Cytokeratin 8 and 18, although it is not known whether these proteins contribute to the malignant phenotype of the cells. Expression of Cytokeratin 8 and 18 in oral squamous cell carcinomas is an independent prognostic marker that indicates a poor prognosis. Cytokeratin 8 expression correlates with malignancy in leukoplakia and carcinomas of the head and neck; it is expressed in all non-small-cell lung cancers. Cytokeratin 8 has been shown to possess extracellular epitopes on tumor cells, which may represent valuable targets for therapy.
Application Dilution
WB 1:300-5000
FCM 1:20-100
IHC-P 1:200-400
IF(ICC) 1:50-200
IHC